Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01029262 · ClinicalTrials.gov registry record · Phase 3
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 239
- Enrollment target
NCT01029262 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 239 participants.
The verdict
NCT01029262, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 239 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether lenalidomide would reduce the number of red blood cell transfusions (RBC) needed in anemic (RBC transfusion-dependent) participants with low or intermediate-1 risk MDS without a deletion 5q chromosome abnormality. The study also investigated the safety of lenalidomide use in these participants. Two-thirds of the participants received oral lenalidomide and one-third of the participants received oral placebo.
Interventions
- OTHER Placebo
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2010-01-26 |
| Est. Completion | 2018-05-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01029262
The ClinicalTrials.gov registry entry for NCT01029262 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01029262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01029262 about?
NCT01029262 is a clinical study titled "A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q". The purpose of this study is to investigate whether lenalidomide would reduce the number of red blood cell transfusions (RBC) needed in anemic (RBC transfusion-dependent) participants with low or intermediate-1 risk MDS without a deletion 5q chromosome abnormality. The study also investigated the sa...
What is the current status of trial NCT01029262?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 239 participants. The study started on 2010-01-26. Estimated completion is 2018-05-09.
What interventions are being tested in trial NCT01029262?
The interventions under investigation include: Placebo (OTHER), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01029262?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.